HomeBUSINESS
BUSINESS

Atezolizumab-Avastin Combo Delivers Positive Data in 1st Line RCC: Chugai
(Dec.12.2017)

Chugai Pharmaceutical said on December 11 that its anti-PD-L1 antibody atezolizumab, also known as Tecentriq, in combination with its older cancer drug Avastin (bevacizumab) delivered positive PIII data for first-line renal cell carcinoma (RCC) in PD-L1-positive patients ...
(LOG IN FOR FULL STORY)